Imunon, Inc. (0HUZ.L)
USD 0.83
(-0.97%)
USD 0.83
(-0.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.03 Million USD | 15.61% |
| 2022 | -24.92 Million USD | -18.63% |
| 2021 | -21 Million USD | -13.64% |
| 2020 | -18.48 Million USD | 10.11% |
| 2019 | -20.56 Million USD | 2.37% |
| 2018 | -21.06 Million USD | -14.06% |
| 2017 | -18.46 Million USD | 10.56% |
| 2016 | -20.64 Million USD | 0.94% |
| 2015 | -20.84 Million USD | 10.64% |
| 2014 | -23.32 Million USD | -51.38% |
| 2013 | -15.41 Million USD | 30.4% |
| 2012 | -22.14 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.01 Million USD | -0.04% |
| 2024 Q1 | -5.01 Million USD | 16.02% |
| 2023 Q3 | -3.9 Million USD | 28.68% |
| 2023 FY | -21.03 Million USD | 15.61% |
| 2023 Q4 | -5.96 Million USD | -52.86% |
| 2023 Q1 | -5.68 Million USD | 17.93% |
| 2023 Q2 | -5.47 Million USD | 3.7% |
| 2022 Q3 | -6.17 Million USD | -3.28% |
| 2022 FY | -24.92 Million USD | -18.63% |
| 2022 Q4 | -6.92 Million USD | -12.18% |
| 2022 Q2 | -5.97 Million USD | -2.33% |
| 2022 Q1 | -5.84 Million USD | -6.39% |
| 2021 Q1 | -5.38 Million USD | -12.3% |
| 2021 FY | -21 Million USD | -13.64% |
| 2021 Q2 | -5.07 Million USD | 5.79% |
| 2021 Q4 | -5.49 Million USD | -8.48% |
| 2021 Q3 | -5.06 Million USD | 0.19% |
| 2020 Q3 | -4.15 Million USD | 12.74% |
| 2020 Q4 | -4.79 Million USD | -15.25% |
| 2020 FY | -18.48 Million USD | 10.11% |
| 2020 Q2 | -4.76 Million USD | -0.02% |
| 2020 Q1 | -4.76 Million USD | -0.39% |
| 2019 Q3 | -5.38 Million USD | 3.27% |
| 2019 Q1 | -4.86 Million USD | -23.04% |
| 2019 FY | -20.56 Million USD | 2.37% |
| 2019 Q4 | -4.74 Million USD | 11.88% |
| 2019 Q2 | -5.56 Million USD | -14.59% |
| 2018 Q2 | -8.01 Million USD | -87.13% |
| 2018 Q1 | -4.28 Million USD | 8.55% |
| 2018 FY | -21.06 Million USD | -14.06% |
| 2018 Q4 | -3.95 Million USD | 1.79% |
| 2018 Q3 | -4.02 Million USD | 49.79% |
| 2017 Q4 | -4.68 Million USD | -6.44% |
| 2017 FY | -18.46 Million USD | 10.56% |
| 2017 Q3 | -4.39 Million USD | 3.78% |
| 2017 Q2 | -4.57 Million USD | 5.14% |
| 2017 Q1 | -4.81 Million USD | 6.14% |
| 2016 Q4 | -5.13 Million USD | 8.27% |
| 2016 Q2 | -4.74 Million USD | 8.46% |
| 2016 FY | -20.64 Million USD | 0.94% |
| 2016 Q1 | -5.17 Million USD | -4.69% |
| 2016 Q3 | -5.59 Million USD | -18.05% |
| 2015 Q4 | -4.94 Million USD | -16.61% |
| 2015 Q3 | -4.24 Million USD | 19.11% |
| 2015 Q2 | -5.24 Million USD | 18.22% |
| 2015 Q1 | -6.41 Million USD | 10.1% |
| 2015 FY | -20.84 Million USD | 10.64% |
| 2014 Q3 | -5.84 Million USD | -9.41% |
| 2014 Q4 | -7.13 Million USD | -21.96% |
| 2014 FY | -23.32 Million USD | -51.38% |
| 2014 Q2 | -5.34 Million USD | -2.76% |
| 2014 Q1 | -5.2 Million USD | -69.86% |
| 2013 Q1 | -4.76 Million USD | 8.54% |
| 2013 Q3 | -3.53 Million USD | 8.17% |
| 2013 Q4 | -3.06 Million USD | 13.34% |
| 2013 FY | -15.41 Million USD | 30.4% |
| 2013 Q2 | -3.84 Million USD | 19.27% |
| 2012 Q4 | -5.21 Million USD | 0.0% |
| 2012 FY | -22.14 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 87.569% |
| Dynavax Technologies Corporation | -37.02 Million USD | 43.204% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -299.135% |
| Perrigo Company plc | 151.9 Million USD | 113.845% |
| Illumina, Inc. | -1.06 Billion USD | 98.033% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.307% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 95.434% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.851% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 101.064% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 80.988% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.52% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 52.917% |
| Waters Corporation | 817.67 Million USD | 102.572% |
| Biogen Inc. | 1.29 Billion USD | 101.622% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 92.325% |
| Evolus, Inc. | -49.23 Million USD | 57.284% |
| Adicet Bio, Inc. | -152.03 Million USD | 86.168% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 82.69% |
| bluebird bio, Inc. | -244.26 Million USD | 91.39% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 86.481% |
| FibroGen, Inc. | -281.81 Million USD | 92.538% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 101.558% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 53.346% |
| Homology Medicines, Inc. | -48.25 Million USD | 56.418% |
| Geron Corporation | -193.94 Million USD | 89.156% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 92.547% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 71.385% |
| Myriad Genetics, Inc. | -123.7 Million USD | 82.999% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 79.142% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 95.919% |
| Zoetis Inc. | 3.06 Billion USD | 100.685% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 56.368% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 101.934% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 110.816% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.488% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 46.287% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 94.055% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 92.38% |
| Verastem, Inc. | -92.08 Million USD | 77.162% |
| Nektar Therapeutics | -137.42 Million USD | 84.697% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 90.928% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 78.399% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 92.148% |
| OPKO Health, Inc. | -157.02 Million USD | 86.607% |
| Exelixis, Inc. | 170.88 Million USD | 112.307% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 108.382% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 119.603% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 62.281% |
| uniQure N.V. | -282.87 Million USD | 92.565% |
| Blueprint Medicines Corporation | -486.27 Million USD | 95.675% |
| Insmed Incorporated | -709.62 Million USD | 97.036% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 106.23% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 94.628% |
| TG Therapeutics, Inc. | 20.63 Million USD | 201.926% |
| Incyte Corporation | 620.52 Million USD | 103.389% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 97.105% |